Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hepatocellular carcinoma therapeutics - Enzo Biochem

Drug Profile

Research programme: hepatocellular carcinoma therapeutics - Enzo Biochem

Alternative Names: Leptin - Enzo Biochem

Latest Information Update: 30 Sep 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzo Biochem
  • Class Intracellular signalling peptides and proteins; Peptide hormones
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 30 Sep 2009 Discontinued - Preclinical for liver cancer in USA (unspecified route)
  • 11 Jul 2005 Preclinical trials in liver cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top